We are live on ! Find out more
JUNO

Juno Therapeutics, Inc.
JUNO

Delisted

JUNO was delisted on the 5th of March, 2018.

Back to rankings

173 hedge funds and large institutions have $2.28B invested in Juno Therapeutics, Inc. in 2017 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 52 increasing their positions, 50 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 3 → 6 (+3)

80% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 20

47% more capital invested

Capital invested by funds: $1.55B → $2.28B (+$731M)

10% more funds holding

Funds holding: 157 → 173 (+16)

4% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 50

31% less call options, than puts

Call options by funds: $31.1M | Put options by funds: $45.3M

Holders
173
Holders Change
+16
Holders Change %
+10.19%
% of All Funds
4.31%
Holding in Top 10
6
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+100%
% of All Funds
0.15%
New
36
Increased
52
Reduced
50
Closed
20
Calls
$31.1M
Puts
$45.3M
Net Calls
-$14.2M
Net Calls Change
-$9.58M

Top Buyers

Rank Fund Capital Flow
1
RG
Redmile Group
California
+$54.8M
2
O
OrbiMed
New York
+$22.6M
3
Jennison Associates
Jennison Associates
New York
+$18.7M
4
WA
Wasatch Advisors
Utah
+$16.3M
5
Morgan Stanley
Morgan Stanley
New York
+$14.5M

Top Sellers

Rank Fund Capital Flow
1
HM
HealthCor Management
New York
-$11.7M
2
BCM
Biomark Capital Management
Connecticut
-$7.51M
3
Norges Bank
Norges Bank
Norway
-$6.21M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$4.5M
5
PP
Peconic Partners
New York
-$3.33M
Name Holding Trade Value Shares
Change 		Change in
Stake
Royal Bank of Canada
151
Royal Bank of Canada
Ontario, Canada
$26K -$121K -4,899 -84%
Northwestern Mutual Wealth Management
152
Northwestern Mutual Wealth Management
Wisconsin
$24K -$19.7K -800 -50%
Fifth Third Bancorp
153
Fifth Third Bancorp
Ohio
$15K – – –
AWMS
154
Advocacy Wealth Management Services
Georgia
$12K – – –
Bessemer Group
155
Bessemer Group
New Jersey
$10K +$8.66K +351 New
AIL
156
AGF Investments LLC
Ontario, Canada
$9K -$1.48K -60 -16%
FANJ
157
Financial Architects (New Jersey)
New Jersey
$9K – – –
TDC
158
Thompson Davis & Co
Virginia
$7K +$6.17K +250 New
HT
159
Heritage Trust
Oklahoma
$6K – – –
HNB
160
Huntington National Bank
Ohio
$6K +$4.93K +200 New
TCOV
161
Trust Company of Vermont
Vermont
$4K – – –
BWM
162
Baystate Wealth Management
Massachusetts
$3K – – –
EWM
163
Edge Wealth Management
New York
$3K – – –
SBL
164
Sargent Bickham Lagudis
Colorado
$3K – – –
LWM
165
Lenox Wealth Management
Ohio
$3K +$2.47K +100 New
PCP
166
Proficio Capital Partners
Massachusetts
$2K – – –
SEI Investments
167
SEI Investments
Pennsylvania
$2K +$1.26K +51 New
QCG
168
Quadrant Capital Group
Ohio
$1K – – –
TCM
169
Tradewinds Capital Management
Washington
$1K – – –
TWA
170
TCI Wealth Advisors
Arizona
$1K +$666 +27 New
MAM
171
Meeder Asset Management
Ohio
$1K +$1.23K +50 New
HM
172
HealthCor Management
New York
– -$11.7M -525,000 Closed
PP
173
Peconic Partners
New York
– -$3.33M -150,000 Closed
AA
174
ALPS Advisors
Colorado
– -$2.02M -91,082 Closed
EAM
175
Eventide Asset Management
Massachusetts
– -$2M -90,000 Closed
4 5 6
7
8

JUNO Hedge Fund Activity: Q2 2017 in Review

173 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Juno Therapeutics, Inc. (JUNO) for Q2 2017, worth a combined $2.28B — up 47% from $1.55B a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new JUNO positions and 20 closed out — a net gain of 16 holders — while 52 added to existing stakes and 50 trimmed.

The largest buyer was Redmile Group, opening a new position worth an estimated $54.8M. The largest seller was HealthCor Management, exiting entirely with an estimated $11.7M sold.

  • 173 institutional investors held Juno Therapeutics, Inc. (JUNO) as of Q2 2017, up from 157 in Q1 2017.
  • Funds reported $2.28B of Juno Therapeutics, Inc. stock for Q2 2017, up 47% quarter-over-quarter.
  • 36 funds opened new Juno Therapeutics, Inc. positions in Q2 2017 and 20 closed out, a net change of +16 holders.
  • The largest Juno Therapeutics, Inc. buyer in Q2 2017 was Redmile Group, an estimated $54.8M added.
  • The largest Juno Therapeutics, Inc. seller in Q2 2017 was HealthCor Management, an estimated $11.7M sold.

Based on aggregated 13F filings for Q2 2017.